ArticleEnvironmental science & technology2026
Presence of Legacy and Emerging PFAS in Human Liver Specimens Banked in the United States from 2000 to 2024.
Article in Environmental science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Per- and polyfluoroalkyl substances (PFAS) are persistent, bioaccumulative chemicals linked to liver toxicity and metabolic disease. 54 PFAS were measured in 211 adult human livers collected between 2000 and 2024 to reveal temporal trends, relative PFAS abundance, and demographic predictors of hepatic burden. PFAS were detected in 210 individuals, with 15 compounds found in ≥30 livers. Total summed PFAS concentrations decreased by 94% over the 24-year period in weighted linear regression, and by 68% after adjusting for age, sex, and liver health in multivariate models. Since 2019, a ∼950-fold variability in concentration was observed, and the PFAS profile in the liver shifted from sulfonates and carboxylates to proportionally more sulfonamides and fluorotelomers. Sampling year was the strongest predictor of hepatic PFAS concentration in multivariate models. Age was positively associated with several long-chain PFAS, which is consistent with years-long elimination half-lives. Males had higher perfluoroundecanoic acid, perfluorododecanoic acid, and 9-chlorohexadecafluoro-3-oxanonane-1-sulfonic acid concentrations, whereas females had higher 8:2 fluorotelomer sulfonic acid concentrations. Nonalcoholic fatty liver disease was associated with lower concentrations of seven PFAS. While legacy PFAS declined following phaseouts, other PFAS increasingly drive liver burdens, with our data showing targeted PFAS comprise <10% of extractable organofluorine, highlighting the inadequacy of substance-by-substance regulatory approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.